QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-downgrades-io-biotech-to-hold

TD Cowen analyst Yaron Werber downgrades IO Biotech (NASDAQ:IOBT) from Buy to Hold.

 crude-oil-falls-sharply-carnival-posts-upbeat-earnings

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded do...

Core News & Articles

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

 hc-wainwright--co-downgrades-io-biotech-to-neutral

HC Wainwright & Co. analyst Emily Bodnar downgrades IO Biotech (NASDAQ: IOBT) from Buy to Neutral.

 nasdaq-jumps-150-points-us-pending-home-sales-rise

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market ...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 io-biotech-plans-to-design-new-registrational-study-for-cylembio-for-treatment-of-first-line-patients-with-advanced-melanoma-implements-restructuring-reducing-workforce-by-50

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical tri...

 io-biotech-issues-update-on-regulatory-pathway-for-cylembio-following-pre-bla-meeting-with-fda-fda-recommends-that-io-biotech-not-submit-bla-based-on-data-from-iob-013-clinical-trial

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical tri...

 io-biotech-to-present-phase-3-and-final-phase-2-trial-results-for-io102-io103-cancer-vaccine-plus-pembrolizumab-at-2025-esmo-congress

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine p...

 io-biotech-q2-eps-040-misses-035-estimate

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) ...

 morgan-stanley-maintains-overweight-on-io-biotech-lowers-price-target-to-4

Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target fro...

 io-biotechs-combo-therapy-for-skin-cancer-falls-just-short-eyes-fda-talks-later-this-year

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across mos...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION